The Banner Alzheimer’s Institute and Astra-Zeneca have partnered up in order to provide an answer to the inherent fears associated with the dreadful memory-loss-related disease; Alzheimer’s.

So, what does this collaboration mean for those genetically predisposed to or stricken by the disease? Early diagnosis by employing state-of-the art “PET� technology, in order to map “amyloid deposits�, which accumulate in the brain and thereby lead to the onset of Alzheimer’s. If physicians and patients alike are able to employ such technology being developed by Astra-Zeneca, leaders in the United States for neuroscience, and the Banner Alzheimer’s Institute, renown for its cutting edge research in the field, the treatment and prolongation of patients’ lives appear feasible.

For more information concerning this ground-breaking partnership and that which it entails, please click on the following link http://thenewsroom.com/details/1298028.